mebendazole   Click here for help

GtoPdb Ligand ID: 13427

Synonyms: Emverm® | Vermox®
Approved drug PDB Ligand
mebendazole is an approved drug (FDA (1974))
Compound class: Synthetic organic
Comment: Mebendazole is a long-established broad spectrum anthelmintic drug that is used in human and veterinary medicine. Benzimidazole class compounds like mebendazole interact with the colchicine-binding site of β tubulin and thereby disrupt polymerisation of microtubules. Repurposing of mebendazole for oncological indications has been proposed [1,5-6,8,11], with mechanism of action focussing on tubulin depolymerisation [3,10].

In 2024 mebendazole was identified as a repurposing candidate with potential to treat the rare genetic disorder autosomal dominant polycystic kidney disease (ADPKD) [2]. Transcriptomic and computational drug discovery tools were used to predict mebendazole's ADPKD potential, and this was validated in vitro (using patient-derived 3D kidney cyst cultures) and in mouse models of the disease.

mebendazole is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 79.79
Molecular weight 295.29
XLogP 1.92
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COC(=O)NC1=NC2=C(C=C(C=C2)C(=O)C3=CC=CC=C3)N1
Isomeric SMILES COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
InChI InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
InChI Key OPXLLQIJSORQAM-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Mebendazole has been used clinically since the 1970s to treat infestations of parasitic worms including pinworms, hookworms and roundworms.
Several clinical studies have been designed and actioned to evaluate mebendazole's potential as an oncology drug for solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04771520 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Phase 2 Interventional M.D. Anderson Cancer Center
NCT03925662 Mebendazole as Adjuvant Treatment for Colon Cancer Phase 3 Interventional Tanta University
NCT02644291 Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Phase 1 Interventional Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01729260 Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide Phase 1 Interventional Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03628079 A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin. Phase 1/Phase 2 Interventional Repos Pharma 8
External links Click here for help
For extended ADME data see the following:

Drugs.com